Medical education · Dr. Javier Zimmermann

24 Aug 2026 · In person · Dr. Javier Zimmermann, Christie NHS Foundation Trust · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0120—

Capture insight from this engagement

Location: Christie NHS Foundation Trust
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

APRIL pathway mechanism
Treatment burden and fatigue
Patient-reported outcomes

Scientific content used

Surrogate-endpoint evidence review

Questions raised

How does proteinuria reduction at 9 months translate to eGFR benefit?
Is there any data on APRIL inhibition in FSGS?

Notes

Medical education with community nephrologist at Christie NHS Foundation Trust. Discussed april pathway mechanism, treatment burden and fatigue, patient-reported outcomes.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 2
Depth of exchange: 1
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0120

Audit history (0)

All create, update and approval events for this record

No audit events in sample data